Double-barrel attack on aggressive lymphoma shows promise
NCT ID NCT07538635
First seen Apr 25, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study tests a powerful two-step treatment for people with relapsed or treatment-resistant large B-cell lymphoma that has high-risk features. First, patients receive CAR-T cells (engineered immune cells) followed by a stem cell transplant. The goal is to see if this combination can keep the cancer from coming back for at least a year. The trial will enroll 20 adults and track response rates, side effects, and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK R/R LBCL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhengjiang, 310022, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.